Medications like donanemab (Kisunla) and lecanemab (Leqembi) target amyloid plaques that build up in the brain due to ...

A survey of 1700 Americans 45 and older found that 79% would want to know if they were in the early stages of Alzheimer's.

A team of scientists, including researchers from University College London (UCL), has discovered key differences in how four ...

UW has begun treating patients with donanemab, a new Alzheimer’s medication that may slow cognitive decline in people with early-stage disease.

The father of the dominant theory of Alzheimer’s disease told another eminent researcher he is “causing harm” by criticizing ...

SEATTLE — There's new hope for people in the early stages of Alzheimer's disease. A new medication called donanemab appears ...

Donanemab, made by Eli Lilly and sold under the brand name Kisunla, is not a cure, nor can it reverse memory loss, doctors say. But research has shown that, like its predecessor lecanemab ...

Donanemab works similarly to lecanemab, another promising Alzheimer's drug. Patients on lecanemab need infusions every two weeks, while donanemab is administered once a month. Between his ...

Since then, other amyloid-targeting monoclonal antibodies, lecanemab and donanemab, have been approved by the US Food and Drug Administration (FDA) for early Alzheimer’s disease. 3 Importantly ...

A new report from the Alzheimer's Association indicates people feel that the earlier they know about a diagnosis, the sooner they can seek treatment options.